Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

491
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
491
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

1.0K
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
1.0K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

335
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
335
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

588
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
588
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

161
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
161

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consideration for Assessing Data/Models/Tools Expiration Supporting Drug Development and Clinical Decision Making.

Therapeutic innovation & regulatory science·2025
Same author

Crowdsourcing Proposal Supporting Patient Engagement in Parkinson's Disease: A Digital Research Environment (DRE)-Enabled, Patient Swarm Approach to Develop QSP Models.

Journal of clinical pharmacology·2025
Same author

Unlocking the Mysteries of Rare Disease Drug Development: A Beginner's Guide for Clinical Pharmacologists.

Clinical and translational science·2025
Same author

Innovations and Best Practices for Therapeutic Development in Pediatric Rare Diseases: A Model-Informed Drug Development Perspective.

Clinical pharmacology and therapeutics·2025
Same author

Consideration of the Root Causes in Candidate Attrition During Oncology Drug Development.

Clinical pharmacology in drug development·2024
Same author

Artificial Intelligence Opportunities to Guide Precision Dosing Strategies.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2024

Related Experiment Video

Updated: May 5, 2026

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

17.2K

Paediatric models in motion: requirements for model-based decision support at the bedside.

Jeffrey S Barrett1

  • 1Department of Pediatrics, Division of Clinical Pharmacology and Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

British Journal of Clinical Pharmacology
|November 21, 2013
PubMed
Summary

Individualized paediatric pharmacotherapy relies on understanding patient factors and drug interactions. Predictive models and model-based decision support systems are advancing to optimize drug dosing for children.

Keywords:
decision supportmodelspaediatricpersonalized medicine

More Related Videos

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
07:01

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

936
Quantified Assessment of Infant's Gross Motor Abilities Using a Multisensor Wearable
09:24

Quantified Assessment of Infant's Gross Motor Abilities Using a Multisensor Wearable

Published on: May 17, 2024

2.8K

Related Experiment Videos

Last Updated: May 5, 2026

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

17.2K
A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
07:01

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

936
Quantified Assessment of Infant's Gross Motor Abilities Using a Multisensor Wearable
09:24

Quantified Assessment of Infant's Gross Motor Abilities Using a Multisensor Wearable

Published on: May 17, 2024

2.8K

Area of Science:

  • Pharmacology and Pharmaceutical Sciences
  • Pediatric Medicine
  • Biomedical Informatics

Background:

  • Optimal pediatric pharmacotherapy requires understanding individual patient status, including development, disease, and concurrent medications.
  • Advances in understanding size and maturation effects on pharmacokinetic/pharmacodynamic (PK/PD) phenomena enable predictive modeling for personalized therapy.

Purpose of the Study:

  • To highlight the necessity of coordinated, systematic approaches for reliable model-based decision support in pediatric pharmacotherapy.
  • To emphasize the development of model-based systems for comprehensive pediatric dosing guidance, ensuring current best practices.

Main Methods:

  • Development of predictive models for individualizing pediatric therapy based on PK/PD understanding.
  • Creation of model-based systems to guide caregivers in pediatric dosing.
  • Emphasis on incorporating diverse global data (demographics, ethnicity, diet, lifestyle) for system evolution.

Main Results:

  • Predictive models can be developed to individualize pediatric pharmacotherapy, particularly when monitoring drug effects or concentrations.
  • Model-based systems are under development to provide comprehensive dosing guidance for pediatric patients.
  • Multidisciplinary involvement and engagement of clinical champions are critical for the clinical validation of these systems.

Conclusions:

  • Model-based systems are essential for advancing pediatric pharmacotherapy, requiring robust guidance aligned with current best practices.
  • These systems must be adaptable, evolving with new information and diverse global data inputs.
  • Adherence to regulatory requirements and software development best practices is crucial for routine clinical integration.